CS MEDICA announces the Malaysian approval of CANNASEN® Protective Nasal Gel. This important approval not only brings an innovative product to the market but symbolizes CS MEDICA's breakthrough in overcoming the complex regulatory barriers in Asia. 

A Milestone for CS MEDICA

Lone Henriksen, CEO of CS MEDICA, comments, "This approval is a monumental achievement for CS MEDICA. Our journey to this point has been marked by a commitment to our goals and a persistent determination to navigate and comply with diverse regulatory environments. Securing approval in Malaysia signifies our successful compliance and paves the way for future opportunities in Asia."

Lone continues, "The successful registration of CANNASEN® Protective Nasal Gel in Malaysia is a breakthrough moment, signaling CS MEDICA's capability to penetrate the Asian market, previously challenging due to stringent regulatory standards. Our new compliance and market strategy sets a strong foundation for introducing additional regional products with the potential to revolutionize the medical device industry by providing innovative solutions for autoimmune diseases."

Future Prospects:

CS MEDICA is positioned to leverage the momentum to expand its product range throughout Asia. The insights gained and the strategies developed through this process are key to smoothing the pathway for future registrations, especially towards markets such as China.

About the Protective Nasal Gel:

CANNASEN® Protective Nasal Gel offers an effective, natural solution for preventing allergies, hay fever, and viral infections. It serves as a moisturizing nasal gel that not only hydrates but also fortifies nasal mucous membranes against pollutants, airborne particles, bacteria, and viruses by forming a protective barrier over the mucous membranes in the nose.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/